den Boer Margriet, Davidson Robert N
Campaign for Access to Essential Medicines, Médecins Sans Frontières, Rue Lausanne 78 CP 116 CH-1211, Geneva 21, Switzerland.
Expert Rev Anti Infect Ther. 2006 Apr;4(2):187-97. doi: 10.1586/14787210.4.2.187.
This review summarizes the current developments in therapy for visceral leishmaniasis. With the recent introduction of new drugs, the main limits in reducing deaths from visceral leishmaniasis are difficulty in diagnosis in the field and health inequality--patients lack of access to treatment. No new drugs are currently in the early stages of development. There are good reasons for the use of combination therapy; to prevent further development of resistance against the limited therapeutic options available.
本综述总结了内脏利什曼病治疗的当前进展。随着近期新药的引入,降低内脏利什曼病死亡率的主要限制在于现场诊断困难以及健康不平等——患者无法获得治疗。目前没有新药处于研发早期阶段。使用联合疗法有充分的理由;以防止对现有有限治疗选择产生进一步的耐药性。